Regeneron Receives CHMP’s Positive Opinion Recommending the Approval of Libtayo (cemiplimab) for NSCLC and BCC

 Regeneron Receives CHMP’s Positive Opinion Recommending the Approval of Libtayo (cemiplimab) for NSCLC and BCC

Regeneron Receives CHMP’s Positive Opinion Recommending the Approval of Libtayo (cemiplimab) for NSCLC and BCC

Shots:

  • The CHMP recommended the approval of Libtayo as a 1L treatment for adults with NSCLC expressing PD-L1 in ≥50% of tumor cells with no EGFR, ALK or ROS1 aberrations, based on the P-III EMPOWER-Lung 1 study
  • The positive opinion of Libtayo in LA and mBCC is based on P-II EMPOWER-BCC 1 study in patients who either progressed on HHI therapy, had not had an objective response after 9mos. on HHI therapy, or were intolerant of prior HHI therapy
  • The EC is expected to decide on both indications in the coming months

Click here to­ read full press release/ article | Ref: Regeneron | Image: Investros Business Daily

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post